|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
ES2293638T3
(es)
|
1994-03-25 |
2008-03-16 |
Isotechnika, Inc. |
Mejora de la eficacia de farmacos por deuteracion.
|
|
AU5122796A
(en)
|
1995-03-31 |
1996-10-16 |
Drug Delivery System Institute, Ltd. |
Amidite derivatives and oligonucleotide derivatives
|
|
CN100406065C
(zh)
|
2000-12-01 |
2008-07-30 |
细胞工厂治疗公司 |
糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
|
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
|
EP1768998A2
(en)
|
2004-04-27 |
2007-04-04 |
Alnylam Pharmaceuticals Inc. |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
|
AU2005247509C1
(en)
|
2004-05-27 |
2012-09-20 |
Alnylam Pharmaceuticals, Inc. |
Nuclease resistant double-stranded ribonucleic acid
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
EP1789553B1
(en)
|
2004-06-30 |
2014-03-26 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
|
WO2006093526A2
(en)
|
2004-07-21 |
2006-09-08 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
|
AU2005330637B2
(en)
|
2004-08-04 |
2012-09-20 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
|
EP1791567B1
(en)
|
2004-08-10 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
US7919472B2
(en)
|
2004-09-17 |
2011-04-05 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
|
WO2006119619A1
(en)
|
2005-05-06 |
2006-11-16 |
Replicor Inc. |
Oligonucleotides inhibiting cell proliferation
|
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
AU2007211082B2
(en)
|
2006-01-27 |
2012-09-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
|
WO2007090071A2
(en)
|
2006-01-27 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｃｓｋ９の発現を調節するための化合物および方法
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
ES2526295T5
(es)
|
2006-10-18 |
2021-05-04 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
WO2009064920A2
(en)
|
2007-11-13 |
2009-05-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
WO2009073809A2
(en)
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
US9290534B2
(en)
|
2008-04-04 |
2016-03-22 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
|
|
EP2321414B1
(en)
|
2008-07-25 |
2018-01-10 |
Alnylam Pharmaceuticals, Inc. |
Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
|
|
AU2009298802A1
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
|
DK2356129T3
(da)
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
AU2010221419B2
(en)
|
2009-03-02 |
2015-10-01 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
|
US9512164B2
(en)
|
2009-07-07 |
2016-12-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide end caps
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
US9012421B2
(en)
|
2009-08-06 |
2015-04-21 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
US8877439B2
(en)
|
2009-12-17 |
2014-11-04 |
Sirna Therapeutics, Inc. |
Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications
|
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011139699A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
|
EP2601204B1
(en)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
|
US9518259B2
(en)
|
2010-06-15 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
|
US9243246B2
(en)
|
2010-08-24 |
2016-01-26 |
Sirna Therapeutics, Inc. |
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
WO2013033223A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
SI3366775T2
(sl)
|
2011-11-18 |
2025-12-31 |
Alnylam Pharmaceuticals, Inc. |
Modificirana sredstva RNAI
|
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
AU2013296321B2
(en)
|
2012-08-03 |
2019-05-16 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
|
EP2906255B1
(en)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
CA2900238A1
(en)
|
2013-02-22 |
2014-08-28 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
EP3066105A4
(en)
|
2013-11-06 |
2017-10-11 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having disulfide groups
|
|
CA2935426C
(en)
*
|
2014-01-30 |
2023-07-25 |
F. Hoffmann-La Roche Ag |
Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
|
|
EP3119789B1
(en)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
CA2950960A1
(en)
|
2014-06-06 |
2015-12-10 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having bioreversible and non-bioreversible groups
|
|
EP3151839A4
(en)
|
2014-06-06 |
2018-02-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
CN106795200B
(zh)
|
2014-10-10 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
Galnac亚磷酰胺、其核酸缀合物及其用途
|
|
EP3904366A1
(en)
|
2014-12-16 |
2021-11-03 |
Novartis AG |
End capped nucleic acid molecules
|
|
WO2016138017A1
(en)
|
2015-02-23 |
2016-09-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing antisense activity
|
|
JP2018528783A
(ja)
|
2015-09-25 |
2018-10-04 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
コンジュゲートアンチセンス化合物及びその使用
|
|
PL4119569T3
(pl)
|
2015-11-06 |
2024-11-18 |
Ionis Pharmaceuticals, Inc. |
Sprzężone związki antysensowne do zastosowania w terapii
|
|
EP3485016A4
(en)
|
2016-07-15 |
2020-03-18 |
Ionis Pharmaceuticals, Inc. |
CONNECTIONS AND METHOD FOR MODULATING TRANSCRIPT PROCESSING
|
|
CA3033867A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
SG11201901841TA
(en)
|
2016-09-02 |
2019-03-28 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands
|
|
US11400161B2
(en)
*
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
TWI788312B
(zh)
*
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
|
DK3607069T3
(da)
|
2017-04-05 |
2022-11-21 |
Silence Therapeutics Gmbh |
Produkter og sammensætninger
|
|
IL269517B2
(en)
|
2017-04-05 |
2025-01-01 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof
|
|
MX2019012280A
(es)
*
|
2017-04-11 |
2020-01-23 |
Arbutus Biopharma Corp |
Composiciones dirigidas.
|
|
EA202090720A1
(ru)
|
2017-09-14 |
2020-07-07 |
Янссен Байофарма, Инк. |
ПРОИЗВОДНЫЕ GalNAc
|
|
CN111527206A
(zh)
|
2017-11-13 |
2020-08-11 |
赛伦斯治疗有限责任公司 |
用于抑制靶标基因表达的包含二硫代磷酸酯键的核酸
|
|
US11725208B2
(en)
|
2017-12-14 |
2023-08-15 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3728281A1
(en)
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Chirally-enriched double-stranded rna agents
|
|
WO2019157531A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
EP3775209A1
(en)
|
2018-04-05 |
2021-02-17 |
Silence Therapeutics GmbH |
Sirnas with at least two ligands at different ends
|
|
WO2019217397A2
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for improving strand biased
|
|
CU20200082A7
(es)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
JP7384833B2
(ja)
|
2018-05-16 |
2023-11-21 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
オフターゲット効果が低下した修飾ｒｎａ剤
|
|
US20210355493A1
(en)
|
2018-10-05 |
2021-11-18 |
Ionis Pharmaceuticals, Inc. |
Oligonucleotide mediated no-go decay
|
|
WO2020072883A1
(en)
|
2018-10-05 |
2020-04-09 |
Ionis Pharmaceuticals, Inc. |
Chirally enriched oligomeric compounds
|
|
WO2020097044A1
(en)
|
2018-11-09 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Modified double stranded oligonucleotides
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
AU2020279101B2
(en)
|
2019-05-17 |
2025-07-24 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
CA3164050A1
(en)
|
2019-12-09 |
2021-06-17 |
Empirico Inc. |
Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
|
|
WO2022140365A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
|
WO2022261005A1
(en)
*
|
2021-06-07 |
2022-12-15 |
Empirico Inc. |
Treatment of angptl4 related diseases
|
|
US11879125B2
(en)
|
2022-03-16 |
2024-01-23 |
Empirico Inc. |
GalNAc compositions for improving siRNA bioavailability
|